ACTIV-2 will begin by testing a monoclonal antibody treatment in volunteers with mild or moderate cases of the disease.

Tuesday, August 4, 2020 NIH Clinical Trial to Test Antibodies and Other Experimental Therapeutics for Mild and Moderate COVID-19 NIAID is supporting a set of adaptive treatment studies for COVID-19, part of the ACTIV public-private partnership, which are designed to test a variety of therapeutics with speed and flexibility. ACTIV-2 will begin by testing a monoclonal antibody treatment in volunteers with mild and moderate cases of the disease, who do not require hospitalization. Additional investigational therapeutics may be tested later in this study. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107